Showing results for "Splunk"
technology
Cash-Rich Cisco Shifts to Net Debt Position for Growth, ReturnsFor Cisco Systems Inc., the $28 billion acquisition of Splunk Inc. marks not only its biggest diversification effort to date but a historic shift to a net debt capital position designed to bolster growth and shareholder returns.March 21, 2024
markets
Bloomberg Markets With Katie Greifeld 03/18/2024"Bloomberg Markets" follows the market moves across every global asset class and discusses the biggest issues for Wall Street. Guests include: Sarah Kunst, Cleo Capital Managing Director; Chuck Robbins, Cisco CEO; Gary Steele, Former Splunk CEO; Martin Daum, Daimler Truck CEO; Arun Sundararajan, NYU Stern School of Business Professor. (Source: Bloomberg)March 18, 2024
business
Bloomberg Talks: Cisco CEO, Former Splunk CEO (Podcast)Cisco completed the acquisition of Splunk on Monday, setting the foundation for delivering unparalleled visibility and insights across an organization’s entire digital footprint. Cisco CEO Chuck Robbins and former Splunk CEO Gary Steele talk about the deal with host Katie Greifeld.March 18, 2024
markets
How Cisco Will Integrate Splunk Into CompanyCisco Systems Inc. officially closed its $28 billion deal to buy Splunk Inc. Cisco CEO Chuck Robbins and former Splunk CEO Gary Steele talk about how they will merge the companies. They say this deal will be good for customers and there is not much product overlap. They appear on "Bloomberg Markets." (Source: Bloomberg)March 18, 2024
markets
AbbVie Sells $15 Billion of Bonds to Buy ImmunoGen, CerevelPharmaceutical giant AbbVie Inc. sold $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings.February 22, 2024
markets
AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&APharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.February 21, 2024